Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children.
We describe the role of intravitreal anti-vascular endothelial growth factor (VEGF) agents in Coats' disease in children. In a prospective, interventional, non-randomized case series, three patients (three eyes) aged 16, seven and two years were diagnosed to have Coats' disease. In Case 1 (16 yr/ male) with macular edema, previous laser photocoagulation being unsuccessful, intravitreal pegaptanib sodium (Macugen) was tried. Case 2 (seven yr/ male) and Case 3 (two yr/ female) were diagnosed to have Stage 4 Coats' and underwent external needle drainage, laser photocoagulation, SF6 gas injection and intravitreal injection of bevacizumab (Avastin). Reduction of exudation and attached posterior pole (Cases 2 and 3) was seen at a follow-up of six months and two months respectively. Intravitreal anti-VEGF agents may be successfully used as adjunct treatment in select cases of Coats' disease in childhood.
Kaul
Shalini
S
Department of Pediatric Ophthalmology and Strabismology, Aditya Jyot Eye Hospital Pvt Ltd, Mumbai, India.
Uparkar
Mahesh
M
Mody
Kruti
K
Walinjkar
Jaydeep
J
Kothari
Mihir
M
Natarajan
S
S
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D000068258:Bevacizumab; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D004322:Drainage; D005260:Female; D006801:Humans; D007267:Injections; D017075:Laser Coagulation; D008297:Male; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D012171:Retinal Vessels / Q000473:pathology*; D013684:Telangiectasis / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D041623:Tomography, Optical Coherence; D014057:Tomography, X-Ray Computed; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab